Drugs for Neglected Diseases initiative - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
33
About the Report
About the Report
Summary
Drugs for Neglected Diseases initiative (DNDi) is a non-profit drug research and development (R&D) organization which discovers and develops new drugs for neglected diseases. The organization develops therapeutics for the treatment of various diseases such as human African trypanosomiasis (HAT, or sleeping sickness), leishmaniasis, and Chagas disease, and conducts research and development projects for other neglected diseases including malaria, paediatric HIV, mycetoma, hepatitis C, and filarial infections. It offers treatments which include ASAQ, ASMQ, NECT, SSG&PM and pediatric benznidazole. It also offers research programs for various organizations. It collaborates with private biotechnology companies, public institutions, academia and NGOs. The organization operates in Switzerland, the US, Kenya, India, Brazil, Malaysia and Japan. DNDi is headquartered in Geneva, Switzerland.
Drugs for Neglected Diseases initiative-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Drugs for Neglected Diseases initiative, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Takeda Pharma Enters into Agreement with DNDi 11
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 12
Optibrium Enters into Partnership with Imperial College London and DNDi 13
Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 14
Institut Pasteur Korea Enters into Research Agreement with DNDi 15
DNDi Enters into Agreement with Takeda Pharma 16
Bayer HealthCare Enters into Co-Development Agreement with Drugs for Neglected Diseases Initiative 17
Celgene Global Health Expands Research Agreement DNDi 18
Institut Pasteur Korea and DNDi Enter into Research Agreement 19
Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 20
Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 21
Astrazeneca Enters into Agreement with DNDi for Neglected Diseases 22
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 23
Drugs for Neglected Diseases initiative-Key Employees 24
Drugs for Neglected Diseases initiative-Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Strategy And Business Planning 27
Nov 08, 2017: DNDi/GARDP opens new South Africa liaison office, hosted by South African Medical Research Council 27
Corporate Communications 28
Aug 08, 2017: DNDi welcomes Dr Marie-Paule Kieny as new Chair of the Board of Directors with Prof. Marcel Tanner stepping down after ten successful years 28
Government and Public Interest 29
Sep 12, 2018: New hope for PKDL patients in Africa as clinical trial aims to make treatment safer and easier 29
Apr 13, 2018: Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa 30
Feb 06, 2018: New open source drug discovery project aims to develop mycetoma treatment 31
Other Significant Developments 32
Jan 18, 2018: Epichem Awarded One Year Contract Extension from DNDi 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33
List of Figure
List of Figures
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List of Table
List of Tables
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Key Facts 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Drugs for Neglected Diseases initiative, Deals By Therapy Area, 2012 to YTD 2018 8
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Takeda Pharma Enters into Agreement with DNDi 11
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 12
Optibrium Enters into Partnership with Imperial College London and DNDi 13
Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 14
Institut Pasteur Korea Enters into Research Agreement with DNDi 15
DNDi Enters into Agreement with Takeda Pharma 16
Bayer HealthCare Enters into Co-Development Agreement with Drugs for Neglected Diseases Initiative 17
Celgene Global Health Expands Research Agreement DNDi 18
Institut Pasteur Korea and DNDi Enter into Research Agreement 19
Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 20
Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 21
Astrazeneca Enters into Agreement with DNDi for Neglected Diseases 22
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 23
Drugs for Neglected Diseases initiative, Key Employees 24
Drugs for Neglected Diseases initiative, Other Locations 26
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.